Member Bulletin Board

Cyber Security Awareness & Response, Lunch & Learn

By California Life Sciences Member: Ice Consulting

Cyber Pandemic impact on Life Science industry (10 min) Cybersecurity challenges under current business and political environment (15 min) Solutions of addressing cybersecurity challenges (20 min) Q&A (15 minutes) All attendees will receive a $25 Amazon Gift Card. Read more….

Cellipont Announces Additions to Senior Leadership Team

By California Life Sciences Member: Cellipont

Poway, CA, March 15, 2022 — Cellipont Bioservices, a contract development and manufacturing organization (CDMO) with more than 15 years of experience in manufacturing cell therapies, today announced the addition of several experienced cell therapy executives to its leadership team. Read more….

ARE, Announces Long-Term Lease With Bristol Myers Squibb for a New 427,000 RSF Innovative Research Hub in the San Diego Cluster Market

By California Life Sciences Member: Alexandria

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations, today announced that Bristol Myers Squibb (BMS) has executed a long-term lease for the development of the global biopharmaceutical company’s newest core R&D facility, an iconic 427,000 RSF world-class building at Alexandria Point. Located in the heart of the University Town Center (UTC) submarket in San Diego, Alexandria Point is the company’s first leading-edge, highly sustainable amenity-rich mega campus. Read more…

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

By California Life Sciences Member: Zai Lab

Zai Lab Limited, a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) who have not been treated with a ROS1 tyrosine kinase inhibitor (TKI). Read more…

Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

By California Life Sciences Member: Bristol Myers Squibb

Bristol Myers Squibb today announced $7.965 million in new health equity grants to 24 U.S. non-profit organizations that aim to improve access and quality care to medically underserved patients and communities across oncology, cardiology, immunology and hematology therapeutic areas. These grants will bolster community outreach and education, increase patient support and care coordination services, and support diversity, cultural competency and collaboration among community health workers and patient navigators in communities across the U.S. To date, Bristol Myers Squibb’s total support in addressing health disparities as part of our 2020 Commitments is just over $39 million. Read more…

Explora BioLabs Launches Preclinical Vivarium Model in Seattle

By California Life Sciences Member: Explora Biolabs

Explora BioLabs, the national provider of industry-leading preclinical vivarium research space and management services headquartered in San Diego, recently announced its entry into the Seattle market. Its first Seattle vivarium, conveniently located in the East Lake Union neighborhood, will open in May 2022. A second facility will open in 36 months in the South Lake Union neighborhood. The new facilities will provide Seattle biotechnology companies with easily accessible vivaria and research space for their mission-critical preclinical in vivo programs. Read more…

San Diego Cell Therapy CDMO acquired by Healthcare-Focused Private Equity Firm

By California Life Sciences Member: Cellipont Bioservices

Performance Cell Manufacturing (“PCM”), a contract development and manufacturing organization (“CDMO”) with more than 15 years of experience in manufacturing cell therapies, today announced that it has been acquired by Great Point Partners (“GPP”), a Greenwich, Connecticut based private investment firm focused on the healthcare industry. As part of the transaction, the company also announced that it will operate under a new name: Cellipont Bioservices. Read more…

Dr. Aletta Schnitzler Joins TurtleTree as Chief Scientific Officer

By California Life Sciences Member: TurtleTree

Cell-based nutrition company TurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO). With her world-class expertise in cellular bioprocessing, Dr. Schnitzler’s appointment marks a significant stride in TurtleTree’s journey towards sustainable and efficient cellular food production. Read more…

Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, [email protected] and MBC BioLabs

By California Life Sciences Member: Bristol Myers Squibb

Bristol Myers Squibb Company announced five innovative biotech startups as winners of the company’s 2021 Golden Ticket Contests. The winners are: RADD Pharmaceuticals and Rubik Therapeutics (LabCentral, Cambridge, MA), Waypoint Bio ([email protected], New York, NY) and Altay Therapeutics and VastBiome (MBC BioLabs, San Francisco Bay Area, CA). Read more…

Corning Accelerates Delivery of Life-Saving Treatments and Critical Drugs with Expanded Pharmaceutical Glass Packaging Portfolio

By California Life Sciences Member: Corning

Corning Incorporated introduced Corning Velocity® Vials, specially engineered Type I borosilicate vials externally coated with the company’s proprietary technology, which are helping industry-leading drugmakers respond to the pandemic at speed. The increased efficiency and throughput enabled by Velocity Vials can drive faster manufacturing of COVID-19 vaccines, helping address industry supply chain challenges and meet global demand. Read more…

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

By California Life Sciences Member: Bristol Myers Squibb

The Bristol Myers Squibb Foundation (BMSF), together with its partners, National Medical Fellowships (NMF) and the American Association for Cancer Research (AACR), today announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program (BMSF DCTCDP). The 52 early-stage investigators are the first of 250 community-oriented clinical trialists who will be trained through the program by 2027. Read more…

Protecting Your Organization from Security Breaches

By California Life Sciences Member: ICE Consulting, Inc.

During the last year and a half, security events have exploded both in numbers and scope, and cyber events have transformed society in numerous unfortunate ways. With soaring costs of these events and the potential of more bold plans from malicious actors, it’s important that companies protect their valuable assets—from intellectual property to research data, as well as business deals and partnerships. Read more…

New Publication Reveals Ebolavirus-Neutralizing Monoclonal Antibodies

By California Life Sciences Member: Abterra Biosciences

In this study, we characterize the circulating antibody response to ebolavirus Glycoproteins (GPs) at the molecular level by identifying monoclonal antibodies (mAbs) that are present in convalescent plasma collected from an Ebolavirus disease survivor. For these mAbs we report the reactivity breadth, epitope specificity, prevalence in plasma, functional activities, and capacity to mediate in vivo protection. Read more…

Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response

By California Life Sciences Member: XPose Therapeutics

Cancer will directly affect the lives of over one-third of the population. The DNA Damage Response (DDR) is an intricate system involving damage recognition, cell cycle regulation, DNA repair, and ultimately cell fate determination, playing a central role in cancer etiology and therapy. Read more…

CHO Plus Announces Acceptance Into BLUE KNIGHT™

By California Life Sciences Member: CHO Plus

CHO Plus, an early-stage innovation company developing technology to dramatically increase the productivity of cells used to manufacture therapeutic proteins and viruses, announced today that it has been accepted into Blue Knight, and will receive funding to support their JLABS @ South San Francisco residency. Read more…

Promaxo Announces Sale of In-Office MRI to Advanced Urology Medical Offices

By California Life Sciences Member: Promaxo

Promaxo, Inc., a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Advanced Urology Medical Offices (Advanced Urology). FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. Read more…

Explora BioLabs Opens New Facility in San Diego, Calif.

By California Life Sciences Member: Explora Biolabs

Explora BioLabs, a national provider of industry-leading preclinical vivarium research space and management services based in San Diego, opened a new facility here on August 23, 2021. Read more…

Carnegie Mellon University and Emerald Cloud Lab to Build World’s First University Cloud Lab

By California Life Sciences Member: Emerald Cloud Lab

Carnegie Mellon University and Emerald Cloud Lab (ECL) have entered into a partnership to build the world’s first cloud lab in an academic setting. The remote-controlled lab will provide a universal platform for artificial intelligence-driven experimentation and revolutionize how academic laboratory research and education are done. Read more…

R&D Tax Credits and the Orphan Drug Credit: Key Differences and Benefits

By California Life Sciences Member: Moss Adams

Two of the most lucrative tax credits available to life sciences companies are the R&D credit and orphan drug credit (ODC). Both incentives provide companies with immediate or future tax benefits intended to reduce the cost of their development operations. Read more…

Micronoma, University of New South Wales Tackle Liver Cancer with $4 Million Grant

By California Life Sciences Member: Micronoma

Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage via microbiome-driven liquid biopsy technology, today announced a collaboration with the University of New South Wales, Sydney for a $4 million grant from the Australian Government to fund research into hepatocellular carcinoma, the most common type of primary liver cancer. Read more…

Public Markets Reflect Long-Term Growth Opportunity for Life Sciences Companies

By California Life Sciences Member: RSM 

Don’t miss out on the latest life sciences insights from RSM Senior Analysts Adam Lohr and Steve Kemler. In this edition of The Real Economy: Industry Outlook, they share data-driven insights on market trends and emerging issues facing life sciences companies. Read more…

What is Low-Volume, High-Complexity Manufacturing?

By California Life Sciences Member: Goddard

One of the trickiest transitions within the product development process is when a product’s design is gearing up for manufacturing. It’s one thing to look at a design’s renderings or prototypes – but production is when things start to feel very real. One way to ease the transition to manufacturing is by partnering with a product developer that can also handle low-volume, high-complexity manufacturing. Read more…